|
시장보고서
상품코드
2008164
양자 세포치료 시장 : 유형별, 용도별, 최종사용자별, 지역별Adoptive Cell Therapy Market, By Type (CAR-T, TCR-T, NK, TIL), By Application (Lymphoma, Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) |
||||||
양자 세포치료 시장은 2026년에 124억 5,000만 달러로 추정되고 있으며, 2033년까지 224억 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 12.1%로 성장할 것으로 전망되고 있습니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준연도 | 2025년 | 시장 규모(2026년) | 124억 5,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간의 CAGR(2026-2033년) | 12.10% | 예측 금액(2033년) | 224억 달러 |
양자세포치료(ACT)는 T세포(면역세포의 일종)를 환자에게 투여하여 암과 같은 질병을 퇴치하는 데 도움을 주는 면역치료의 일종입니다. 입양 세포 치료의 유형에는 키메라 항원 수용체(CAR) T세포, T세포 수용체(TCR) T세포, 종양침윤림프구(TIL), 자연살해(NK) 세포 등이 있습니다. 조혈모세포치료는 실험실에서 대량으로 배양한 면역세포를 체내에 투여해 암을 공격하게 하는 치료법입니다. 흑색종을 자연적으로 인식하는 면역세포를 사용하기도 하고, 흑색종 세포를 인식하여 사멸시킬 수 있도록 변형된 면역세포를 사용하기도 합니다. 입양세포치료는 T세포이식요법, 세포성 면역요법이라고도 불립니다.
시장 역학
세계의 입양 세포 치료 시장에서 활동하는 주요 기업은 제품 출시, 제휴, 자금 조달과 같은 성장 전략을 채택하는 데 주력하고 있으며, 이는 예측 기간 중 시장 성장을 촉진할 것으로 예상됩니다. 예를 들어 2021년 1월 글로벌 임상단계 바이오제약 기업 Gracell Biotechnologies Inc.는 다발성골수종 치료를 위한 자사의 FasTCAR 탑재형 BCMA/CD19 이중 표적 CAR-T 세포치료제 'GC012F'에 대해 미국 식품의약국(FDA)이 희귀질환 치료제로 지정했다고 발표했습니다. (FDA)가 희귀질환 치료제 지정을 부여했다고 발표했습니다. 또한 2019년 11월에는 다발성 고형암 치료를 위한 T세포 수용체(TCR) 유도 유도형 입양세포치료제를 개발중인 바이오제약 기업 Zelluna Immunotherapy와 임상 단계에 있는 자연살해(NK) 세포 제조 선도기업 Glycostem Therapeutics BV가 개발, 라이선스 및 공급에 관한 계약을 체결했다고 발표했습니다. Zelluna Immunotherapy와 Glycostem Therapeutics BV와의 이번 제휴는 암 환자 치료를 위한 동종 TCR 유도 NK 세포치료제(TCR-NK)의 개발 및 제조에 초점을 맞추고 있습니다.
이 보고서의 주요 특징
- 세계의 입양세포치료제 시장에 대해 조사분석했으며, 2021년을 기준연도로 하여 예측기간(2022-2030년) 시장 규모와 연평균 성장률(CAGR)에 대해 조사분석한 보고서입니다.
- 또한 각 부문의 잠재적 매출 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요 인사이트를 제공합니다.
- 이 보고서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등의 매개 변수를 기반으로 세계의 입양세포치료제 시장의 주요 기업 개요을 제공합니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계의 입양 세포 치료 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 입양세포치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 양자 세포치료 시장 : 유형별(2026-2033년)
제5장 양자 세포치료 시장 : 용도별(2026-2033년)
제6장 양자 세포치료 시장 : 최종사용자별(2026-2033년)
제7장 양자 세포치료 시장 : 지역별(2026-2033년)
제8장 경쟁 구도
제9장 섹션
KSA 26.05.04Adoptive Cell Therapy Market is estimated to be valued at USD 12.45 Bn in 2026 and is expected to reach USD 22.4 Bn by 2033, growing at a compound annual growth rate (CAGR) of 12.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 12.45 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 12.10% | 2033 Value Projection: | USD 22.4 Bn |
Adoptive cell therapy (ACT) is a type of immunotherapy in which T cells (a type of immune cell) are given to a patient to help the body fight diseases, such as cancer. Types of adoptive cell therapy include chimeric antigen receptor (CAR) T cells, T cell receptor (TCR) T cells, tumor infiltrating lymphocytes (TILs), and natural killer (NK) cells. Adoptive cell therapy involve use of immune cells that are grown in the lab in large numbers followed by administering them to the body to fight cancer. Sometimes, immune cells that naturally recognize melanoma are used, while other times they are modified to make them recognize and kill the melanoma cells. Adoptive cell therapy is also called T-cell transfer therapy, and cellular immunotherapy.
Market Dynamics
Key players operating in the global adoptive cell therapy market are focusing on adoption of growth strategies such as product launch, collaboration, and fundraise which are expected to drive the market growth during the forecast period. For instance, in January 2021, Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for GC012F, Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting CAR-T cell therapy for the treatment of multiple myeloma. Moreover, in November 2019, Zelluna Immunotherapy, a biopharma company developing T-cell receptor (TCR) guided adoptive cell therapy products for the treatment of multiple solid cancers, and Glycostem Therapeutics BV, a clinical stage and leading Natural Killer (NK) cell manufacturing company announced that they have entered into a development, license and supply agreement. This collaboration between Zelluna Immunotherapy and Glycostem Therapeutics BV will focus on the development and manufacture of allogeneic TCR guided NK cell therapies (TCR-NK's) for the treatment of patients with cancer
Key features of the study
- This report provides an in-depth analysis of the global adoptive cell therapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global adoptive cell therapy market based on the following parameters - Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Novartis AG, Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics, Inc., Transgene SA, Cellectis, ImmunityBio, Inc., Sorrento Therapeutics, bluebird bio, Inc., Arcellx, Sana Biotechnology, Inc., Biodesix, Inc, and Laurus Labs
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global adoptive cell therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global adoptive cell therapy market
Market Segmentation
- By Type
- CAR-T
- TCR-T
- NK
- TIL
- By Application
- Lymphoma
- Leukemia
- Others
- By End User
- Hospitals
- Cancer Treatment Centers
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC Countries
- Israel
- Rest of Middle East & Africa
- Key Players
- Novartis AG
- Gilead Sciences, Inc.
- Castle Creek Biosciences, Inc.
- Lineage Cell Therapeutics, Inc.
- Transgene SA
- Cellectis
- ImmunityBio, Inc.
- Sorrento Therapeutics, bluebird bio, Inc.
- Arcellx, Sana Biotechnology, Inc.
- Biodesix, Inc
- Laurus Labs
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Application
- Market Snapshot, By End User
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Adoptive Cell Therapy Market, By Type, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026- 2033
- Segment Trends
- CAR-T
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- TCR-T
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- NK
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- TIL
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
5. Adoptive Cell Therapy Market, By Application, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Lymphoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
6. Adoptive Cell Therapy Market, By End User, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2026 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
- Cancer Treatment Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (USD Bn)
7. Adoptive Cell Therapy Market, By Region, 2026 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2026-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2026 - 2033, (USD Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Novartis AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Gilead Sciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Castle Creek Biosciences, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Lineage Cell Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Transgene SA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Cellectis
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ImmunityBio, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sorrento Therapeutics
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- bluebird bio, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Arcellx
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Sana Biotechnology, Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Biodesix, Inc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Laurus Labs
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
9. Section
- References
- Research Methodology
- About Us
